Difference between revisions of "Talk:Prostate cancer with neuroendocrine differentiation"

From Libre Pathology
Jump to navigation Jump to search
 
Line 1: Line 1:
== Neuroendocrine staining poor prognosticator ==
== Neuroendocrine staining poor prognosticator ==
https://pubmed.ncbi.nlm.nih.gov/34784097/
== Neuroendocrine (NE) staining without NE morphology ==
The tumour's morphology is NOT in keeping with small cell carcinoma (the tumour cells have too much cytoplasm) and NOT in keeping with large cell neuroendocrine carcinoma (the tumour cells have nucleoli occasionally and eosinophilic cytoplasm).
The distinction between (A) carcinoma and (B) carcinoma with a neuroendocrine component is dependent on: (1) morphology and (2) neuroendocrine (NE) staining.  This case has NE staining; however, it does not have a typical NE morphology.  As such, the case does not having a definite neuroendocrine component.


https://pubmed.ncbi.nlm.nih.gov/34784097/
It should be noted that NE marker positivity is predictive of hormone refractive disease.[1]  Androgen receptor testing in this context has been described as being an additional useful test;[2] however, testing is not available in house.
 
1. J Urol. 2007 Sep;178(3 Pt 1):838-43; quiz 1129. doi: 10.1016/j.juro.2007.05.018. Epub 2007 Jul 16.
2. Mol Clin Oncol. 2013 Mar;1(2):257-262. doi: 10.3892/mco.2013.69. Epub 2013 Jan 14.

Revision as of 17:44, 3 May 2023

Neuroendocrine staining poor prognosticator

https://pubmed.ncbi.nlm.nih.gov/34784097/

Neuroendocrine (NE) staining without NE morphology

The tumour's morphology is NOT in keeping with small cell carcinoma (the tumour cells have too much cytoplasm) and NOT in keeping with large cell neuroendocrine carcinoma (the tumour cells have nucleoli occasionally and eosinophilic cytoplasm).

The distinction between (A) carcinoma and (B) carcinoma with a neuroendocrine component is dependent on: (1) morphology and (2) neuroendocrine (NE) staining. This case has NE staining; however, it does not have a typical NE morphology. As such, the case does not having a definite neuroendocrine component.

It should be noted that NE marker positivity is predictive of hormone refractive disease.[1] Androgen receptor testing in this context has been described as being an additional useful test;[2] however, testing is not available in house.

1. J Urol. 2007 Sep;178(3 Pt 1):838-43; quiz 1129. doi: 10.1016/j.juro.2007.05.018. Epub 2007 Jul 16. 2. Mol Clin Oncol. 2013 Mar;1(2):257-262. doi: 10.3892/mco.2013.69. Epub 2013 Jan 14.

Retrieved from "https://librepathology.org/w/index.php?title=Talk:Prostate_cancer_with_neuroendocrine_differentiation&oldid=52311"